Cancer‐associated prothrombotic pathways: leucocytosis, but not thrombocytosis, correlates with venous thromboembolism in women with ovarian cancer

Risk factors for venous thromboembolism in cancer vary between tumours. Leucocytosis, thrombocytosis, tumour histology and vascular compression may drive thrombosis in ovarian cancer. Thrombosis developed in 13.4% of our patients. Higher median leucocyte, neutrophil and monocyte counts were related to thrombosis. Thrombocytosis >350 × 109/L was frequent (63.8%), but not predictive of thrombosis. Identification of prothrombotic biomarkers may help personalise preventive treatments.

[1]  Xiaofei Liu,et al.  Risk factors and treatment of venous thromboembolism in perioperative patients with ovarian cancer in China , 2018, Medicine.

[2]  Georg Heinze,et al.  A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. , 2018, The Lancet. Haematology.

[3]  N. Mackman,et al.  Cancer-associated pathways and biomarkers of venous thrombosis. , 2017, Blood.

[4]  Y. Ozaki,et al.  C‐type lectin‐like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor‐bearing mice , 2017, Journal of thrombosis and haemostasis : JTH.

[5]  D. Khabele,et al.  Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records , 2016, BMC Cancer.

[6]  H. Gabra,et al.  Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. , 2015, European journal of cancer.

[7]  B. Karlan,et al.  Serum interleukin-6 is a biomarker of survival in women with advanced stage and optimally resected epithelial ovarian cancer , 2015 .

[8]  R. Fonseca,et al.  Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. , 2014, Thrombosis research.

[9]  G. Jayson,et al.  Thrombosis in ovarian cancer: a case control study , 2014, British Journal of Cancer.

[10]  C. Riley,et al.  Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer , 2013, British Journal of Cancer.

[11]  N. Mackman,et al.  Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. , 2013, Blood.

[12]  N. Gleeson,et al.  Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival. , 2013, European journal of obstetrics, gynecology, and reproductive biology.

[13]  A. Bakhru.  Effect of ovarian tumor characteristics on venous thromboembolic risk , 2013, Journal of gynecologic oncology.

[14]  W. Chiu,et al.  Paraneoplastic thrombocytosis in ovarian cancer. , 2012, The New England journal of medicine.

[15]  Jian Wu,et al.  Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. , 2011, Cytokine.

[16]  U. Jaeger,et al.  High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) , 2010, Journal of thrombosis and haemostasis : JTH.

[17]  T. Renné,et al.  Platelet Polyphosphates Are Proinflammatory and Procoagulant Mediators In Vivo , 2009, Cell.

[18]  H. Sørensen,et al.  Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study , 2006, BMC Cancer.

[19]  C. Klersy,et al.  Ovarian cancer and venous thromboembolic risk. , 2005, Gynecologic oncology.

[20]  W. Jelkmann,et al.  Thrombopoietin production in wild-type and interleukin-6 knockout mice with acute inflammation. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.